Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.
Kopeckova K, Buchler T, Bortlicek Z, Hejduk K, Chloupkova R, Melichar B, Pokorna P, Tomasek J, Linke Z, Petruzelka L, Kiss I, Prausova J. Kopeckova K, et al. Among authors: petruzelka l. Target Oncol. 2017 Feb;12(1):89-95. doi: 10.1007/s11523-016-0458-1. Target Oncol. 2017. PMID: 27638381
Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis.
Fiala O, Veskrnova V, Chloupkova R, Poprach A, Kiss I, Kopeckova K, Dusek L, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Boubliková L, Dvorak J, Melichar B, Buchler T. Fiala O, et al. Among authors: petruzelka l. Target Oncol. 2018 Dec;13(6):735-743. doi: 10.1007/s11523-018-0597-7. Target Oncol. 2018. PMID: 30353488
Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis.
Buchler T, Chloupkova R, Poprach A, Fiala O, Kiss I, Kopeckova K, Dusek L, Veskrnova V, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Melichar B. Buchler T, et al. Among authors: petruzelka l. Cancer Manag Res. 2018 Dec 28;11:359-368. doi: 10.2147/CMAR.S183093. eCollection 2019. Cancer Manag Res. 2018. PMID: 30643461 Free PMC article.
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients.
Novakova-Jiresova A, Kopeckova K, Boublikova L, Chloupkova R, Melichar B, Petruzelka L, Finek J, Fiala O, Grell P, Batko S, Linke Z, Kiss I, Prausova J, Buchler T. Novakova-Jiresova A, et al. Among authors: petruzelka l. Cancer Manag Res. 2020 Jul 3;12:5365-5372. doi: 10.2147/CMAR.S255332. eCollection 2020. Cancer Manag Res. 2020. PMID: 32753954 Free PMC article.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C, Láng I, Inbar M, Kahán Z, Greil R, Beslija S, Stemmer SM, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Petruzelka L, Eniu A, Nisenbaum B, Dank M, Anghel R, Messinger D, Brodowicz T; TURANDOT investigators. Zielinski C, et al. Among authors: petruzelka l. Lancet Oncol. 2016 Sep;17(9):1230-9. doi: 10.1016/S1470-2045(16)30154-1. Epub 2016 Aug 5. Lancet Oncol. 2016. PMID: 27501767 Clinical Trial.
Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
Thallinger C, Lang I, Kuhar CG, Bartsch R, Singer CF, Petruzelka L, Melichar B, Knittelfelder R, Brodowicz T, Zielinski C. Thallinger C, et al. Among authors: petruzelka l. BMC Cancer. 2016 Feb 18;16:121. doi: 10.1186/s12885-016-2171-y. BMC Cancer. 2016. PMID: 26887956 Free PMC article. Clinical Trial.
182 results